Predictive factors of axillary pathological complete response in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy - Takeaways - MDSpire

Predictive factors of axillary pathological complete response in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy

  • By

  • Marta Rodríguez de Trujillo Campo-Cossío

  • Sara Romero-Martín

  • Beatriz Rodríguez-Alonso

  • Pilar Font-Ugalde

  • José Luis Raya-Povedano

  • Marina Álvarez-Benito

  • December 24, 2025

  • 0 min

Share

  • 1

    Neoadjuvant chemotherapy combined with anti-HER2 agents can induce axillary pathological complete response in up to 74% of HER2-positive breast cancer cases.

  • 2

    Sentinel lymph node biopsy has become a less invasive alternative to complete axillary lymph node dissection, reducing complications like lymphedema and chronic pain.

  • 3

    Recent guidelines suggest targeted axillary dissection for patients with up to three suspicious nodes who achieve axillary radiologic complete response after neoadjuvant chemotherapy.

  • 4

    Factors predicting axillary pathological complete response in HER2-positive breast cancer include age, initial tumor size, tumor grade, Ki-67, and axillary radiologic response.

  • 5

    The study aims to identify factors influencing axillary pathological complete response to reduce unnecessary lymphadenectomies and improve patient outcomes.

Original Source(s)

Predictive factors of axillary pathological complete response in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy

  • by Marta Rodríguez de Trujillo Campo-Cossío, Sara Romero-Martín, Beatriz Rodríguez-Alonso, Pilar Font-Ugalde, José Luis Raya-Povedano, Marina Álvarez-Benito

  • December 24, 2025

Related Content

Deep Learning Algorithms Versus Radiologists in Digital Breast Tomosynthesis for Breast Cancer Detection: Systematic Review and Meta-Analysis

A Case Study of Atrial Fibrillation Induced by Utidelone in Palliative Chemotherapy for Metastatic Breast Cancer

Evaluation of SPIO-Enhanced MRI in Distinguishing Metastatic Lymph Nodes from Reactive Hyperplasia in Breast Cancer: Diagnostic Efficacy and Correlation with VEGF-C Levels